Copyright: ©Author(s) 2026.
World J Gastroenterol. Jan 21, 2027; 33(3): 123673
Published online Jan 21, 2027. doi: 10.3748/wjg.123673
Published online Jan 21, 2027. doi: 10.3748/wjg.123673
Figure 1 High METTL1 expression is associated with poor clinical prognosis of pancreatic cancer.
A: Immunohistochemical staining and quan titative analysis of METTL1 expression in normal pancreatic and pancreatic adenocarcinoma (PAAD) tissues; B and C: Western blot and Dot blot detection of METTL1 expression in paired peritumoral, primary and peritoneal metastatic tissues; D and E: Univariate and multivariate Cox regression analysis of prognostic related clinical indicators; F: Kaplan-Meier survival curve analysis of overall survival differences between METTL1 high and low expression groups; G: Endogenous METTL1 expression in different PAAD cell lines detected by western blot; H and I: Quantitative polymerase chain reaction and western blot verification of stable METTL1 knockdown and overexpression cell lines (PANC-1 and ASPC-1). Scale bar: 100 μm; bP < 0.01. NS: Not significant; PAAD: Pancreatic adenocarcinoma; m7G: N7-methylguanosine; IHC: Immunohistochemistry; OS: Overall survival.
- Citation: Yang C, Qiu CZ, Yin ZG, Mao Y, Ge XS, Wang F. METTL1-mediated N7-methylguanosine modification promotes glycolysis and H4K5 lactylation-dependent Snail-1 activation in pancreatic adenocarcinoma peritoneal metastasis. World J Gastroenterol 2027; 33(3): 123673
- URL: https://www.wjgnet.com/1007-9327/full/v33/i3/123673.htm
- DOI: https://dx.doi.org/10.3748/wjg.123673